
    
      The study was conducted at 9 centers across the Russia and Kazakhstan. Patients were
      allocated in 2:1 comparison groups for the ONCX and control groups, respectively. A total of
      133 patients were enrolled in the study; 84 in the ONCX group and 49 as controls.

      ONCX contains microelements, vitamins, amino acids and certain naturally occurring,
      biologically active substances.

      It is expected that additional support with certain micronutrients may improve prognosis,
      decrease the frequency of side effects and complications and maintain the Quality of life in
      cancer patients.
    
  